RPL35B Antibody

What is RPL35 and why is it important for research?

RPL35 (Ribosomal Protein L35) is a component of the 60S ribosomal subunit belonging to the L29P family of ribosomal proteins. It is primarily located in the cytoplasm and plays an essential role in protein synthesis. The significance of RPL35 extends beyond basic ribosomal function, as it has been associated with Congenital Muscular Dystrophy due to LMNA mutation .

RPL35 participates in critical biological pathways including viral mRNA translation and rRNA processing in both nucleus and cytosol. Gene Ontology annotations indicate important molecular functions such as poly(A) RNA binding and mRNA binding capabilities . This multifunctionality makes RPL35 antibodies valuable tools for investigating fundamental cellular processes and disease mechanisms related to translation.

What are the main applications of RPL35 antibodies in research?

RPL35 antibodies can be utilized in multiple experimental approaches:

These applications enable researchers to investigate RPL35 expression patterns, localization, and interactions with other proteins in various experimental contexts . When selecting an application, consider the specific research question, sample type, and required sensitivity level.

What species reactivity should I expect from RPL35 antibodies?

Most commercially available RPL35 antibodies demonstrate cross-reactivity with human, mouse, and rat samples . Some antibodies offer broader reactivity profiles that may include cow, pig, and chicken, which is beneficial for comparative studies across species .

When selecting an antibody for a particular experimental system, verify the specific reactivity profile provided by the manufacturer. Sequence conservation analysis between your target species and the immunogen used to generate the antibody can help predict potential cross-reactivity when working with non-validated species.

How should RPL35 antibodies be stored and handled?

For optimal maintenance of antibody activity and specificity, follow these storage recommendations:

• Store at -20°C for up to 1 year from the date of receipt

• Avoid repeated freeze-thaw cycles that can degrade antibody quality

• Most RPL35 antibodies are supplied in a buffer containing PBS with 40-50% glycerol and 0.02-0.05% sodium azide at pH 7.4

• Some formulations may include BSA (0.5%) as a stabilizer

When handling these antibodies, remember that many contain sodium azide, which is toxic and hazardous. Use appropriate safety precautions and dispose of according to institutional guidelines .

What are the common immunogen regions targeted by RPL35 antibodies?

RPL35 antibodies target various epitopes across the protein, with each targeting strategy offering different advantages:

Selection of antibodies targeting specific regions depends on your experimental goals. C-terminal antibodies may be valuable when investigating potential binding partners or regulatory elements, while full-length antibodies might provide stronger signals for general detection purposes .

How do I optimize Western Blot protocols using RPL35 antibodies?

For optimal western blot results with RPL35 antibodies, consider the following methodological approach:

• Sample preparation: Extract proteins using RIPA buffer supplemented with protease inhibitors. RPL35 has a molecular weight of approximately 14.5 kDa, so optimize gel percentage (12-15% SDS-PAGE) accordingly.

• Transfer conditions: Use PVDF membranes for better protein retention and employ semi-dry transfer systems at 15-20V for 30-45 minutes.

• Blocking strategy: Utilize 5% non-fat milk in TBST for 1 hour at room temperature to minimize background.

• Primary antibody incubation: Dilute RPL35 antibody to 1:500-1:2000 in blocking buffer and incubate overnight at 4°C .

• Detection optimization: For low abundance samples, consider signal amplification methods or highly sensitive chemiluminescence substrates.

Remember that RPL35 is abundantly expressed in many cell types, so titrate antibody concentrations carefully to avoid signal saturation.

What are the recommended dilutions for different applications of RPL35 antibodies?

Optimal dilutions vary based on the application and specific antibody characteristics:

Always perform a dilution series during initial optimization to determine the ideal concentration for your specific experimental conditions and sample types . Higher antibody concentrations may increase nonspecific binding, while insufficient antibody can lead to weak signals.

How can I validate the specificity of my RPL35 antibody?

Thorough validation ensures reliable experimental results:

• Positive and negative controls: Use tissues/cells known to express or lack RPL35.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to verify binding specificity.

• Knockdown validation: Compare staining patterns between wild-type and RPL35 knockdown/knockout samples.

• Mass spectrometry correlation: Confirm that immunoprecipitated proteins include RPL35.

• Cross-reactivity analysis: Test against related ribosomal proteins, particularly those in the L29P family.

Antibody validation is particularly important for ribosomal proteins like RPL35 due to their structural similarities and conserved domains across the ribosomal protein family .

What controls should I use when working with RPL35 antibodies?

Implement comprehensive controls to ensure experimental rigor:

• Positive tissue controls: Liver or kidney tissues typically express high levels of RPL35.

• Loading controls: For western blots, use housekeeping proteins like GAPDH or β-actin, adjusting for the significant size difference with RPL35.

• Isotype controls: Include matched isotype control antibodies (typically rabbit IgG) at equivalent concentrations to assess non-specific binding .

• Technical controls: Include no-primary-antibody controls to evaluate secondary antibody specificity.

• Biological controls: When possible, include RPL35-depleted samples as negative controls.

These controls help distinguish genuine RPL35 signal from technical artifacts and enable proper interpretation of experimental results.

How can I troubleshoot common issues with RPL35 antibody staining in immunohistochemistry?

When encountering IHC challenges with RPL35 antibodies, consider these methodological solutions:

• High background:

  • Increase blocking time/concentration (try 5-10% normal serum)

  • Reduce primary antibody concentration (test 1:200-1:300)

  • Include 0.1-0.3% Triton X-100 in wash buffers

• Weak or absent signal:

  • Optimize antigen retrieval (try citrate buffer pH 6.0 at 95°C for 20 minutes)

  • Increase primary antibody concentration (1:50-1:100)

  • Extend incubation time to overnight at 4°C

  • Try signal amplification systems like tyramide signal amplification

• Non-specific staining:

  • Use antigen affinity-purified antibodies

  • Pre-absorb antibody with tissue lysate

  • Optimize washing steps (increase wash times/volumes)

Remember that tissue fixation conditions significantly impact epitope accessibility for RPL35, with formalin fixation times over 24 hours potentially masking target epitopes.

How can I use RPL35 antibodies to study ribosomal assembly and function?

RPL35 antibodies can illuminate ribosomal biogenesis through these advanced approaches:

• Proximity labeling: Combine RPL35 antibodies with BioID or APEX2 systems to identify proximal proteins in the ribosome assembly pathway.

• Polysome profiling: Use RPL35 antibodies to track ribosomal subunit incorporation into translating ribosomes under various cellular conditions.

• Ribosome biogenesis analysis: Apply RPL35 antibodies in pulse-chase experiments to study temporal aspects of ribosomal assembly.

• Structure-function studies: Correlate RPL35 binding patterns with functional ribosomal outcomes through combined immunoprecipitation and translation efficiency assays.

• Stress response investigation: Monitor RPL35 localization changes during cellular stress with immunofluorescence, as the protein participates in pathways related to viral mRNA translation .

These techniques can provide mechanistic insights into the connection between RPL35 and associated disease conditions.

What are the considerations for using RPL35 antibodies in co-immunoprecipitation experiments?

For successful co-immunoprecipitation (co-IP) of RPL35 and its interaction partners:

• Buffer optimization: Use gentle lysis conditions (e.g., 150mM NaCl, 1% NP-40, 50mM Tris pH 7.4) to preserve native protein interactions.

• Cross-linking strategy: Consider reversible cross-linkers like DSP (dithiobis[succinimidyl propionate]) to stabilize transient interactions.

• Antibody selection: Choose antibodies raised against epitopes unlikely to interfere with protein interactions. C-terminal targeting antibodies (AA 85-115) may be optimal .

• Magnetic bead systems: Prefer magnetic beads over agarose for gentler handling and reduced background.

• RNase treatment controls: Include RNase-treated samples to distinguish RNA-dependent from direct protein-protein interactions.

Remember that RPL35's natural context within the ribosome means many interactions may be structurally dependent on the intact ribosomal complex.

Can RPL35 antibodies be used to investigate disease mechanisms related to ribosomal dysfunction?

RPL35 antibodies provide valuable tools for investigating ribosomopathies and translation-related disorders:

• Expression analysis in disease models: Quantify RPL35 levels in tissues from patients with Congenital Muscular Dystrophy due to LMNA mutations, where RPL35 has been implicated .

• Ribosome heterogeneity assessment: Use RPL35 antibodies to evaluate potential compositional differences in ribosomes across disease states.

• Stress granule dynamics: Track RPL35 localization during cellular stress responses, which may reveal disease-relevant mechanisms.

• Tissue-specific translation regulation: Compare RPL35 distribution patterns between affected and unaffected tissues in ribosomopathy models.

• Therapeutic response monitoring: Evaluate changes in RPL35 expression or localization following experimental treatments for translation-related diseases.

These applications can help elucidate how ribosomal protein imbalances contribute to disease pathology and identify potential therapeutic targets.

How can site-specific conjugation techniques improve RPL35 antibody applications?

Advanced conjugation strategies enhance RPL35 antibody functionality:

• Sortase-mediated transpeptidation: This enzymatic approach enables site-specific conjugation of reporters or functional molecules to RPL35 antibodies. The S. aureus sortase A system recognizes LPETG motifs and catalyzes attachment to pentaglycine-modified molecules, creating homogeneous conjugates with precise stoichiometry .

• Click chemistry applications: Incorporating azide or alkyne groups at defined positions on RPL35 antibodies allows bioorthogonal conjugation to various functional moieties.

• Photochemical conjugation: Light-activated crosslinkers can be used for spatiotemporal control of RPL35 antibody modifications.

• Enzyme-specific tags: Adding sortase recognition sequences to RPL35 antibodies enables post-production modification with detection reagents or therapeutic payloads .

These methods produce more consistent conjugates compared to traditional approaches using lysine or cysteine side chains, which create heterogeneous mixtures with variable modification sites and stoichiometries .

What are the latest research findings regarding RPL35's role in disease pathways?

Recent studies have expanded our understanding of RPL35's significance beyond basic ribosomal function:

• Cancer biology: Research indicates altered RPL35 expression in several cancer types, potentially contributing to dysregulated translation of oncogenic mRNAs.

• Neurodegenerative disease connections: RPL35's involvement in RNA binding pathways may link to protein aggregation disorders.

• Muscular dystrophy mechanism: RPL35 has been specifically associated with Congenital Muscular Dystrophy due to LMNA mutations, suggesting a potential role in muscle-specific translation regulation .

• Viral pathogenesis: RPL35's participation in viral mRNA translation pathways highlights its potential role in host-pathogen interactions .

• Therapeutic targeting potential: Emerging evidence suggests that modulating specific ribosomal proteins like RPL35 might offer selective approaches for disease intervention.

These findings underscore the value of RPL35 antibodies as tools for investigating specialized ribosome functions beyond global protein synthesis.

How do I address cross-reactivity concerns with RPL35 antibodies?

Minimizing cross-reactivity issues requires strategic planning:

• Epitope selection: Choose antibodies targeting unique regions of RPL35 rather than conserved ribosomal protein domains. The C-terminal region (AA 85-115) offers greater specificity .

• Absorption protocols: Pre-incubate antibodies with recombinant related proteins (other L-family ribosomal proteins) to remove cross-reactive antibodies.

• Validation across methodologies: Confirm specificity using orthogonal techniques (e.g., mass spectrometry validation of western blot bands).

• Peptide mapping: Perform epitope mapping to identify specific binding regions and predict potential cross-reactivity.

• Monoclonal consideration: For the most stringent applications, consider monoclonal antibodies, though most commercial RPL35 antibodies are polyclonal .

Cross-reactivity is particularly relevant for ribosomal proteins due to their structural and sequence similarities within protein families.

What strategies can improve signal-to-noise ratio when using RPL35 antibodies?

Optimize signal quality with these methodological refinements:

• Blocking optimization: Test various blocking agents (BSA, normal serum, commercial blockers) to identify the optimal formulation for your specific antibody and sample type.

• Antibody purification: Use antigen affinity-purified antibodies, which demonstrate higher specificity than crude antisera. Most quality RPL35 antibodies undergo affinity purification against their immunizing epitopes .

• Sample preparation refinement: For tissue sections, extend fixation washing steps to remove residual fixatives that may contribute to background.

• Titration experiments: Perform detailed antibody dilution series to identify the concentration providing maximum specific signal with minimal background.

• Detection system selection: For challenging samples, enzyme-based amplification systems like tyramide signal amplification can enhance specific signals while maintaining signal-to-noise advantages.

These approaches are particularly valuable when detecting RPL35 in tissues with high autofluorescence or inherent peroxidase activity.

How can I quantitatively assess RPL35 expression levels in different tissues?

For reliable quantitative analysis of RPL35 expression:

• ELISA development: Optimize an ELISA system using RPL35 antibodies at 1:5000-1:10000 dilutions. Non-competitive indirect ELISA formats provide reliable quantification when standardized properly .

• Western blot densitometry: Use calibrated recombinant RPL35 protein standards to generate standard curves for densitometric analysis.

• Digital pathology approaches: Employ automated image analysis software with immunohistochemistry to quantify RPL35 staining intensity across tissue sections.

• Flow cytometry: For cell suspensions, optimize intracellular staining protocols using RPL35 antibodies conjugated to fluorophores.

• qPCR correlation: Correlate protein levels detected by antibodies with mRNA expression to validate quantitative findings.

When developing these assays, remember that as a ribosomal protein, RPL35 expression may vary significantly across tissues and developmental stages.

What are the considerations for using RPL35 antibodies in multiplexed immunofluorescence?

Successfully incorporate RPL35 antibodies into multiplexed imaging by addressing these factors:

• Antibody species selection: Choose RPL35 antibodies raised in species compatible with your multiplexing panel. Rabbit polyclonal RPL35 antibodies are most common but consider mouse monoclonal options when combining with other rabbit antibodies .

• Fluorophore selection: Assign fluorophores based on expected RPL35 expression levels, reserving brightest fluorophores for lower-abundance targets.

• Sequential staining protocols: For challenging combinations, implement sequential staining with intermediate fixation or antibody stripping steps.

• Spectral unmixing: Utilize spectral imaging systems with unmixing algorithms to resolve overlapping fluorophore emissions.

• Validation controls: Include single-stained controls and fluorescence-minus-one controls to confirm antibody performance in the multiplexed context.

RPL35's widespread expression makes it a useful reference marker in some multiplexed applications, particularly when investigating specialized ribosome compositions.

How do post-translational modifications affect RPL35 antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody binding to RPL35:

• Phosphorylation sensitivity: Some RPL35 antibodies may show reduced binding to phosphorylated forms, particularly those targeting regions containing serine/threonine residues.

• Ubiquitination effects: RPL35 undergoes regulatory ubiquitination, which may mask epitopes recognized by antibodies targeting modified regions.

• Methylation considerations: Ribosomal proteins commonly undergo methylation, which can alter antibody binding properties.

• PTM-specific antibodies: Consider developing modification-specific antibodies to study regulatory RPL35 modifications.

• Pretreatment strategies: For some applications, phosphatase treatment or deubiquitinating enzyme pretreatment may enhance antibody recognition by removing interfering modifications.

When investigating stress responses or disease states, remember that PTM patterns on RPL35 may change, potentially affecting antibody recognition and experimental interpretation.